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Abstract
Background: Recently, the accuracies of many commercially available immunoassays for Vitamin D have been
questioned. Liquid chromatography tandem mass spectrometry (LC- MS/MS) has been shown to facilitate accurate
separation and quantification of the major circulating metabolite 25-hydroxyvitamin-D3 (25OHD3) and 25-
hydroxyvitamin-D2 (25OHD2) collectively termed as 25OHD. However, among other interferents, this method may
be compromised by overlapping peaks and identical masses of epimers and isobars, resulting in inaccuracies in
circulating 25OHD measurements. The aim of this study was to develop a novel LC-MS/MS method that can
accurately identify and quantitate 25OHD3 and 25OHD2 through chromatographic separation of 25OHD from its
epimers and isobars.
Methods: A positive ion electrospray ionisation (ESI) LC-MS/MS method was used in the Multiple Reaction
Monitoring (MRM) mode for quantification. It involved i) liquid-liquid extraction, ii) tandem columns (a high
resolution ZORBAX C18 coupled to an ULTRON chiral, with guard column and inlet filter), iii) Stanozolol-D3 as
internal standard, and iv) identification via ESI and monitoring of three fragmentation transitions. To demonstrate
the practical usefulness of our method, blood samples were collected from 5 healthy male Caucasian volunteers;
age range 22 to 37 years and 25OHD2, 25OHD3 along with co-eluting epimers and analogues were quantified.
Results: The new method allowed chromatographic separation and quantification of 25OHD2, 25OHD3, along with
25OHD3 epimer 3-epi-25OHD3 and isobars 1-a-hydroxyvitamin-D3 (1aOHD3), and 7-a-hydroxy-4-cholesten-3-one
(7aC4). The new assay was capable of detecting 0.25 ng/mL of all analytes in serum.
Conclusions: To our knowledge, this is the first specific, reliable, reproducible and robust LC-MS/MS method
developed for the accurate detection of 25OHD (Vitamin D). The method is capable of detecting low levels of
25OHD3 and 25OHD2 together with chromatographic separation from the co-eluting epimers and isobars and
circumvents other instrumental/analytical interferences. This analytical method does not require time-consuming
derivatisation and complex extraction techniques and could prove very useful in clinical studies.
Introduction
Vitamin D plays a vital role in skeletal metabolism, cal-
cium homeostasis, [1-3] and also in the functioning of
the immune, cardiovascular, and reproductive systems
[4,5]. Vitamin D deficiency leads to rickets and osteoma-
lacia and is also associated with breast and colorectal
cancers, multiple sclerosis, dementia, rheumatoid arthri-
tis, diabetes, Parkinson’s and Alzheimer’s diseases [6,7].
Despite numerous reports, the associations of Vitamin
D deficiency with health and diseases are subject
to debate, partly owing to inadequacies in current
approaches to measurement of serum levels. Depending
on the source, Vitamin D is produced in two forms:
Vitamin D2 and Vitamin D3, which differ by the pre-
sence of a double bond and methyl group on the alipha-
tic side chain. The issues involved in assessing Vitamin
D status arise from the complexities of the metabolic
pathways leading to a number of active forms. The com-
plex metabolic pathway for Vitamin D3 is summarized
in Figure 1.
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Vitamin D3 is formed from its precursor 7-dehydro-
cholesterol in the skin by ultraviolet B light (medium
wavelength, 290-315 nm) and Vitamin D2 originates
from dietary sources together with some fraction of D3.
In the liver, Vitamins D3 and D2 undergo hydroxylation
reactions catalyzed by 25-hydroxylase, which leads to
the formation of pharmacologically active metabolites
25OHD3 and 25OHD2 respectively (collectively termed
as 25OHD). Further metabolism (in the presence of 1a,
hydroxylase) in the kidney produces the pharmacologi-
cally active metabolites 1-alpha,25-dihydroxyvitamin-D3
(1a,25(OH)2D2) and 1-alpha,25-dihydroxyvitamin-D2
(1a,25(OH)2D3) along with the minor metabolite 24,25
(OH)2D3 [8-10].
Since 25OHD has significant effects on health and
wellbeing, there has been a substantial interest in
improving the relevant analytical techniques [11-30].
Owing to a long serum half-life, measurement of total
25OHD (25OHD2 and 25OHD3) is the routinely used
approach for assessing the total circulating Vitamin D
status [10-14]. In immunoassay techniques, a measure of
total metabolite concentration and equivalent detection
of both 25OHD2 and 25OHD3 is challenging, as bind-
ing proteins show a higher affinity for 25OHD3 than
25OHD2 [15-18]. Reports have shown inter-laboratory
and inter-method variations in results for Vitamin D
determinations [19-21].
LC-MS/MS is currently the best technique available
for the correct quantification of 25OHD3 and 25OHD2
[22,23] and it also has the capability to overcome most
of the problems associated with protein binding assays.
LC-MS/MS is a more favourable technique because
sample derivatisation is not required, run time is very
short and an internal standard is used which usually
compensates for any matrix related and instrumental
effects [24-32].
However, the LC-MS/MS approach is also subject
to interferences [33-37]. Along with matrix related,
instrumental and analytical interferences, endogenous
25OHD determinations have also been shown to suffer
from epimeric and isobaric interferences [38-41]. Epimers
are non-super imposable (or non mirror images) that
only differ in the configuration at one carbon atom
(Figure 2). Epimers and isobars are compounds with the
same molecular weight as Vitamin D metabolites and
form the same mass to charge parent and product ion
pairs upon ionisation. Moreover, the separation of inter-
fering epimers and isobars is also essential, because they
can overlap chromatographically with Vitamin D metabo-
lites or internal standard peaks and give false estimates of
true Vitamin D levels. 25OHD3 is the most abundant
Vitamin D metabolite in circulation and 3-epi-25OHD3
is the most prevalent epimer of 25OHD3. There are two
compounds known to cause isobaric interferences in
25OHD analysis; 1a-hydroxyvitamin-D3 (1aOHD3),
which is an exogenous pharmaceutical compound and
7a-hydroxy-4-cholestene-3-one (7aC4), which is an
endogenous bile acid precursor [30,38-43].
The epimerization of 25OHD3 and 1a,25-(OH)2D3
results in the formation of 3-epi-25OHD3 and 3-epi-
1a,25(OH)2D3 epimers respectively as shown in Figure
2. The epimers of 25OHD differ in configuration at
third carbon atom (C-3) (shown by dashed highlights in
Figure 2) that is attached to a hydroxyl group. Hydroxy-
lation of 3-epi-25OHD3 forms 3-epi-1a,25(OH)2D3 [41].
The aim of this study was to develop a novel LC-MS/
MS method that can accurately identify and quantitate
25OHD3 and 25OHD2 and chromatographically sepa-
rate epimers and isobars.
Materials and methods
Blood samples
Blood samples (100 mL) were obtained from 5 healthy,
male, Caucasian volunteers of age ranging from 22 to
37 years, weight ranging from 72.1-98.1 kg (mean weight
84.86 ± 11.3 kg) and height ranging from 165-190 cm
Figure 1 Metabolic pathways for Vitamin D3 [8-10].
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(mean height 179.5 ± 8.6 cm). Blood samples were centri-
fuged at 1500 g and serum was extracted. The serum sam-
ples were frozen individually in labelled, amber, plastic
vials [29]. To minimise assay variations, a multilevel serum
calibrator set (Chromsystems, Germany) was used for pre-
paration of calibration curves and quality controls. The
lyophilised calibrators (based on human serum) consisted
of 3 high and 1 low-level calibrators and were handled in
the same manner as volunteer specimens. According to
the assay procedures, the calibrators were analysed along
with routine samples to meet the standards outlined by
National Institute of Standards and Technology (NIST)
[44,45].
Standards and reagents
GV-65C (3 mL syringe) mixed bed cation exchange col-
umns were obtained from Biochemical Diagnostics,
(New York, USA), Bond Elut-SI, Bond Elut Plexa, Bond
Elut LMS, Bond Elut PPL, SampliQ OPT and SampliQ
DVB solid phase extraction cartridges were purchased
from Agilent Technologies (Cheshire, UK). 25OHD3,
25OHD2, 1-a-hydroxyvitamin-D3 (1aOHD3), 3-epi-
25OHD3, hexane, isopropanol, methanol, dichloro-
methane, deionised water, formic acid, acetonitrile,
ammonium hydroxide, pentane and ether were obtained
from Sigma Aldrich (Poole, UK). 7-a-hydroxy-4-choles-
ten-3-one (7aC4) and stanozolol-D3 (internal standard)
were obtained from LGC standards (Teddington, UK).
All chemicals and reagents were of HPLC grade.
Preparation of standards and samples
Stock solutions of all analytes were prepared in methanol
to obtain a concentration of 1 mg/mL and stored in
amber vials at -20°C in the dark. Under these conditions,
the stock solutions were found to be stable for 3 months.
The solutions were kept in the dark to minimise light
Figure 2 Epimerisation and metabolic pathways for Vitamin D3 metabolites. [adapted from reference [41]].
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induced degradation of Vitamin D [46,47]. Working solu-
tions were made in methanol by serial dilution of stock
solutions. Working internal standard solution was also
prepared by diluting the stock solution of internal stan-
dard with methanol to a final concentration of 1 μg/mL.
Calibrators and internal standard solutions made in-
house were stable for 2 weeks when stored at -20°C. The
lyophilised serum calibrators were reconstituted in HPLC
grade water and allowed to stand for 10 to 15 minutes at
room temperature. The vials were then swirled to dis-
solve the contents until homogeneity. The lyophilized
reference serum calibrants were stable for 3 months
when stored at -20°C [46,47]. The calibration curves and
quality controls were prepared from the multilevel refer-
ence calibrator set in the range 0.5 to 84.4 ng/mL
concentrations, respectively. Different methods and con-
ditions for sample pretreatment and extraction were
undertaken to optimise recovery, specificity and signal to
noise ratio. The sample pretreatment and extraction
methods [12-32] were adopted as follows.
Sample pretreatment
Serum samples were thawed; vortex mixed and equili-
brated at room temperature for 15 minutes and 25 μL
of working solution of stanozolol-D3 (internal standard)
was added to all samples. Formic acid (2 M, 50 μL) was
added and the resultant solution vortexed. Then 3 mL
of methanol/isopropanol (1:1, v/v) mixture was added
and vortexed to release the protein bound analyte and
to promote protein precipitation during a 15 minutes
incubation at 4°C. The suspended matter was removed
after centrifugation at 3500 g for 5 minutes at 4°C. The
supernatants were transferred to clean amber glass
tubes. The remaining solution was subjected to further
sample purification, as follows.
Liquid-Liquid extraction (LLE)
Different solvent mixtures were tested for liquid-liquid
extraction: namely; heptane, methanol, propanol,
dichloromethane, acetonitrile and hexane. Hexane/
dichloromethane (1:1, v/v) mixture was found to give
optimum extraction recovery. For liquid-liquid extrac-
tion a 3 mL hexane/dichloromethane mixture (1:1, v/v)
was added to the supernatant after protein precipitation
and the solution was vigorously vortexed for 1 minute
and then centrifuged at 3500 g for 5 minutes at 4°C.
The supernatant layer was transferred to clean, amber,
glass tubes. The residual lower layer of the serum sam-
ple was further extracted twice with the hexane/dichlor-
omethane (1:1, v/v) mixture. The organic phase
obtained was pooled and dried under a gentle stream of
nitrogen at room temperature. It was then reconstituted
in 200 μL of HPLC grade methanol/water (1:1, v/v)
mixture. Solid phase extraction (SPE) was also tested as
an alternative to the liquid-liquid extraction technique.
Solid phase extraction (SPE)
A range of different sorbent packing materials was
tested for SPE purification: namely, Biochemical Diag-
nostics’s GV-65C cation exchange columns and Agilent
Technologies range columns (Bond Elut Plexa, Bond
Elut LMS, Bond Elut PPL, Bond Elut-SI, SampliQ OPT
and SampliQ DVB). Agilent Bond Elut-SI silica gel
(3 mL, 500 mg) was found to give the optimum elution
recovery. For SPE extraction, the cartridges were first
activated with hexane, followed by addition of methanol
and equilibration with water. The samples were then
loaded onto the SPE cartridges and extracted using
gravity. The cartridges were washed with 3 mL water
and then 3 mL methanol before drying by applying a
negative pressure for 5 minutes in a vacuum manifold.
Different eluents were tried for best elution recovery:
namely; methanol, acetonitrile, 2% formic acid in metha-
nol, methanol/propanol mixture (1:1, v/v), NH4OH
(2 M, 50 μL/acetonitrile 3 mL) and ether/hexane mix-
ture (1:1, v/v). The optimum elution recovery was
achieved with 3 mL ether/hexane mixture (30:70, v/v).
The residues were dried under a gentle stream of nitro-
gen at room temperature and reconstituted in 200 μL of
methanol/water mixture (1:1, v/v). The recovery of the
LLE method was found to be 11% greater than the cor-
responding SPE method. Thus liquid-liquid extraction
technique was preferred over solid phase extraction. A
schematic representation of serum sample purification
for analysis using LC-MS/MS is shown in Figure 3.
LC-MS/MS procedure
The LC-MS/MS system consisted of an autosampler
(PAL-CTC Analytics, Switzerland), a turbomolecular
pump (1100 series, Agilent Technologies, USA) and a
Figure 3 Schematic diagram showing sample purification and
analysis.
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Triple Quadrupole mass spectrometer (PE-SCIEX API-
3000, Applied Biosystems Division of MDS Health
Group Ltd, Canada). Analyst software version 1.4.2 (AB
SCIEX) was used for results acquisition and quantita-
tion. A 5 μL aliquot of the sample was injected into the
LC-MS/MS system for analysis. Samples were analysed
in the low light conditions, as it has been observed that
Vitamin D has a greater stability under these conditions
[46,47]. An Agilent microbore ZORBAX SB-C18 RRHD
column (2.1 mm × 100 mm, 1.8 μm) was used in tan-
dem prior to an ULTRON ES-OVM Chiral column (2
mm × 150 mm, 5 μm) for analysis. A low dispersion
inlet filter (frit diameter 2.1 mm) was installed prior to
the Agilent column to minimise external band spreading
and improve peak shapes. A chiral guard column
(ULTRON ES-OVM) of specification (4 mm × 10 mm)
was also placed post filter and prior to the Agilent col-
umn to minimise interferences caused by instrumental
and matrix contaminants. The column oven temperature
was maintained at 40°C. Different mobile phases and
their gradient compositions were tested for best results.
Optimum peak resolution was achieved using 0.1% for-
mic acid in acetonitrile (solvent A) and 0.1% formic acid
in water (solvent B). Gradient composition of the two
solvents is shown in Figure 4. The total flow rate
through the columns was 200 μL/min.
The mass spectrometer was operated in positive elec-
trospray ionisation (ESI) mode at a spray voltage of 5000
V and capillary temperature of 450°C. The generated pro-
tonated molecules of 25OHD3, 25OHD2, 3-epi-25OHD3,
1aOHD3, 7aC4 and stanozolol-D3 (internal standard)
were used as precursor ions for collision activated disso-
ciation (CAD) into product ions in MS-MS analysis.
Results
Calibration curves and quality controls at low, medium
and high concentration levels were prepared from the
multi-level reference standards with known amounts of
25OHD. The assays were validated for specificity, recov-
ery, linearity and intraday/interday precision and accu-
racy. The lower limit of detection (LLOD) for all
analytes was found to be 0.25 ng/mL. The LLOD was
determined by decreasing the analyte concentrations
until a response equivalent to 3 times the background
level was observed. The relative extraction recoveries at
a final concentration of 50 ng/mL were determined by
comparing the representative peak areas of extracted
analytes (N = 6) to un-extracted analytes. The un-
extracted analyte solutions were prepared in methanol.
Validation results are summarised in Table 1.
Under- or over-estimation of actual 25OHD3 concen-
trations may occur owing to co-eluting epimers (e.g.3-
epi-25OHD3) and isobars (e.g.7aC4) [39-42]. The use of
high resolution microbore ZORBAX column in tandem
with chiral ULTRON column not only facilitated accu-
rate determination of the analyte ions but also chroma-
tographically separated all isobars and epimers from
25OHD co-eluting peaks.
Multiple reaction monitoring (MRM) mode was used
for the analysis of 25OHD2 and 25OHD3. The MRM
parameters were optimised using direct infusion of 0.1
μg/mL solutions of standard compounds. The MRM
sequence consisted of two periods executed sequentially
to monitor different transition pairs using parameters
optimised for each period. The most abundant MRM
ion transitions for each analyte were acquired using the
conditions given in Table 2.
Figure 4 Mobile phase gradient composition: solvent A (0.1% formic acid in acetonitrile) and solvent B (0.1% formic acid in water).
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According to a joint position statement issued by Brit-
ish Association of Dermatologists, Diabetes UK, the
Multiple Sclerosis Society UK, the National Heart
Forum UK and the National Osteoporosis Society UK,
the threshold level quoted for Vitamin D deficiency is ≤
10 ng/mL (≤ 25 nmol/L) [48]. Individuals with ≤ 10 ng/
mL of 25OHD are regarded as Vitamin D deficient.
Some experts define Vitamin D deficiency as 25OHD
levels ≤ 20 ng/mL [49-51]. However, the levels of Vita-
min D can vary between individuals and currently there
is no standard set for optimal Vitamin D levels [49-51].
Amongst the five samples analysed by LC-MS/MS, three
were found to be below the effective 25OHD levels.
Vitamin D serum results are shown in Table 3.
The levels of potential interference owing to epimers
and isobars are shown in Table 4. Clearly, if not chro-
matographically separated, these interferents could make
a major contribution (in the range of 14 to 55%) to the
total measured level of Vitamin D. The comparison
between levels in Tables 3 and 4 reveals that where epi-
mers and isobars are not accounted for, the measure-
ments of Vitamin D levels are inflated to appear as
normal. In these cases a diagnosis of deficiency may be
missed as illustrated in Figure 5. The percentage of
interfering epimer and isobars in serum, are detailed in
Table 4. The isobar (1aOHD3) was not detected in any
samples.
Discussion
These results confirm the complexities involved in mea-
suring Vitamin D status and reinforce the need for the
uniform adoption of improved accurate assays. Measure-
ments of 25OHD in human serum using competitive
immunoassays are difficult owing to lipophilicity/tight
binding to the Vitamin D-binding protein (DBP), even at
very low serum concentrations [15]. In addition, immu-
noassays for 25OHD have been reported to cross-react
with 24,25(OH)2D3, an intermediate product during
the formation of 1,25(OH)2D3 in the kidney [16,17]
(Figure 1). Many commercial immunoassays can only
measure 25OHD3 and are not suitable to monitor sup-
plementation with Vitamin D2, which is derived from
Table 1 Summary of assay validation results.
Compounds Linear range
(ng/mL)
LLOD
(ng/mL)
Recovery (%)
at 50 ng/mL
Concentration
(ng/mL)
r2 Intraday
(%CV)
Interday
(%CV)
Accuracy (%)
25OHD3 0.5-84.4 0.25 95 12.5 0.9999 2.1 12.1 97.5
25 4.6 6.7 92.9
50 7.1 4.1 92.2
25OHD2 0.5-84.4 0.25 88 12.5 0.9996 7.5 8.1 99.4
25 9.1 8.6 97.5
50 6.8 5.5 101.2
Table 2 Retention times, MRM transitions and ESI
conditions of analytes.
Analytes Retention
time (min)
Transition (m/z)
Precursor® Product
Collision
energy (eV)
401.3 ® 383.1 36
25OHD3 13.5 401.3 ® 365.1 41
401.3 ® 159.2 46
413.3 ® 395.5 46
25OHD2 11.1 413.3 ® 377.2 51
413.3 ® 355.5 53
401.3 ® 383.1 36
3-epi-25OHD3 13.1 401.3 ® 365.1 41
401.3 ® 159.2 46
401.3 ® 383.1 36
1aOHD3 11.1 401.3 ® 365.1 41
401.3 ® 159.2 46
401.3 ® 383.1 36
7aC4 10.5 401.3 ® 365.1 41
401.3 ® 159.2 46
Stanozolol-D3
(I.S)
3.09 332.2 ® 81.2 42
Table 3 Vitamin D serum results.
Volunteers Age 25OHD3 25OHD2 Total 25OHD Total 25OHD 25OHD levels*
(ng/mL) (ng/mL) (ng/mL) nmol/L
1 21 2.8 7.0 9.8 24.0 Low
2 41 11.3 5.2 16.5 40.7 Normal
3 24 3.4 3.3 6.7 16.4 Low
4 33 15.2 2.5 17.7 43.8 Normal
5 38 6.5 2.5 9.0 22.1 Low
*According to ref. 48.
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plant sources and widely used in many countries for for-
tification of foods [18]. Hence, LC-MS/MS analysis is
preferred but it has been shown that it is also subjected
to interference issues [19-28]. In our new method, the
use of an electrospray ionisation technique has overcome
the problems associated with in-source transformation of
25OHD3-sulfate and other metabolites to 25OHD3
which may occur when using atmospheric pressure che-
mical ionisation mode [29].
The use of tandem column technology, an optimised
mobile phase composition and a modified extraction
method not only separate the epimers and isobars but
also eliminates the interferences caused by early eluting
salts (e.g. sodium) and the late eluting phospholipids,
which may interfere with analyte ionisation [29-34].
Moreover, the installation of a low dispersion inlet filter
together with a chiral guard column also minimises the
interferences resulting from early eluting amino acids
and late eluting xenobiotics. The column also separates
interfering compounds present at higher concentration
which have been shown to overlap or share exact mass
transitions with 25OHD e.g. detergents and phthalates
etc [29-31].
The separation of epimers and isobars from the target
analyte is critical because they can overlap 25OHD
peaks and form the same masses upon ionisation, thus
compromising the true status of 25OHD in circulation
[38-43]. The epimer of 25OHD3 is known to have the
same effects on suppressing parathyroid hormone (PTH)
secretion, but it has negligible calcium-producing effects
[40,41]. Recently, it was concluded that the absence of
external standardisation for the 25OHD assay might
lead to greater variations and false results [33]. To mini-
mise the inter-laboratory and inter-method variations in
our LC-MS/MS analysis, we have used reference materi-
als for preparation of our calibrants and quality controls,
along with the introduction of a new internal standard.
The latter was required as, when using the internal stan-
dard hexadeuterated-25OHD3, certain fragment transi-
tions of the parent ions could lead to greater isobaric
interferences such as the transition 407.7 > 389.7 [37].
Stanozolol-D3 as a new internal standard prevents iso-
baric interferences by using the transition 332.2 > 81.2.
To date, only one transition of the parent ion to pro-
duct ion has been investigated, instead of our three-pre-
cursor ions to fragment ions transitions (according to the
Figure 5 Vitamin D levels and co-eluting epimers and isobars in five volunteers.
Table 4 The percentage of interfering epimer (E) and isobars (I) in serum.
Volunteers 25OHD E I 25OHD+E+I Total E+I % E+I
ng/mL ng/mL % ng/mL % ng/mL ng/mL of total
1 9.8 1.8 11.8 3.6 23.7 15.2 5.4 35.5
2 16.5 0.5 2.6 2.3 11.9 19.3 2.8 14.5
3 6.7 2.5 16.7 5.8 38.7 15.0 8.3 55.3
4 17.7 1 4.7 2.5 11.8 21.2 3.5 16.5
5 9 0 0.0 0 0.0 9.0 0 0.0
E = 3-epi-25OHD3, I = 7aC4 and1aOHD3
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qualifier-qualifier principle) [29]. To our knowledge, this
is first time that three transitions of precursor ions to pro-
duct ions have been used for quantification of 25OHD3,
25OHD2, 3-epi-25OHD3, 1aOHD3 and 7aC4 as shown
in Table 2. The sum of the three transitions not only
increases the sensitivity of the assay but also minimises
isobaric interferences.
To summarise, this is the first LC-MS/MS method for
the determination of 25OHD which includes separation
and quantification of epimers and isobars. It is a fast
liquid-liquid extraction method, which does not require
complicated derivatisation procedures, hence reducing
assay time and variability. This method can quantify the
different 25OHD forms accurately, which is difficult to
achieve using immunoassay methods. This methodology
can be used for accurate blood testing to prevent falsely
elevated Vitamin D levels being reported.
Conclusions
The LC-MS/MS method was free from all types of
interferences arising due to epimeric, isobaric, instru-
mental and matrix components, which may interfere
with analyte ionisation. Thus the LC-MS/MS method
provides a robust, specific, reliable and reproducible
technique as a solution to the problems identified in
relation to current assays for Vitamin D. Removal of
uncertainties in Vitamin D measurement, is required in
order to progress the current understanding of the roles
of Vitamin D in health and disease via more rigorous
clinical trials [7].
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